Advanced Certificate in Biopharma Market Access for Generics

-- ViewingNow

The Advanced Certificate in Biopharma Market Access for Generics is a comprehensive course designed to meet the growing industry demand for professionals with expertize in generic drug market access. This certificate program emphasizes the importance of generic drugs in healthcare systems and the complex process of market access for these medications.

5.0
Based on 2,533 reviews

2,068+

Students enrolled

GBP £ 140

GBP £ 202

Save 44% with our special offer

Start Now

ใ“ใฎใ‚ณใƒผใ‚นใซใคใ„ใฆ

Learners will gain in-depth knowledge of the regulatory landscape, pricing policies, and market access strategies specific to generic drugs. By equipping learners with essential skills in this field, the course provides a clear pathway for career advancement in the biopharma industry. The program's rigorous curriculum and industry-recognized certificate make graduates highly sought after by employers in this competitive field. Overall, this course is essential for professionals seeking to deepen their understanding of market access for generic drugs and distinguish themselves as experts in the field.

100%ใ‚ชใƒณใƒฉใ‚คใƒณ

ใฉใ“ใ‹ใ‚‰ใงใ‚‚ๅญฆ็ฟ’

ๅ…ฑๆœ‰ๅฏ่ƒฝใช่จผๆ˜Žๆ›ธ

LinkedInใƒ—ใƒญใƒ•ใ‚ฃใƒผใƒซใซ่ฟฝๅŠ 

ๅฎŒไบ†ใพใง2ใƒถๆœˆ

้€ฑ2-3ๆ™‚้–“

ใ„ใคใงใ‚‚้–‹ๅง‹

ๅพ…ๆฉŸๆœŸ้–“ใชใ—

ใ‚ณใƒผใ‚น่ฉณ็ดฐ

โ€ข Market Access Strategies for Generics: Understanding the landscape of market access for generic drugs, including key stakeholders, regulations, and reimbursement pathways.
โ€ข Health Economics and Outcomes Research: Analyzing the economic and clinical impact of generic drugs, including cost-effectiveness, budget impact analysis, and real-world evidence.
โ€ข Pricing and Reimbursement Policies: Examining pricing and reimbursement policies for generic drugs in different healthcare systems, including reference pricing, value-based pricing, and price volume agreements.
โ€ข Stakeholder Engagement and Management: Identifying and engaging with key stakeholders, including payers, providers, and patients, to optimize market access for generic drugs.
โ€ข Market Access Data Analytics: Leveraging data analytics and market research techniques to inform market access strategies for generic drugs, including pricing, contracting, and distribution.
โ€ข Generic Drug Development and Regulatory Affairs: Understanding the regulatory landscape for generic drug development, including approval pathways, bioequivalence requirements, and post-approval surveillance.
โ€ข Patient Access Programs and Adherence Strategies: Developing patient access programs and adherence strategies to increase the use of generic drugs and improve patient outcomes.
โ€ข Global Market Access Trends and Challenges: Exploring global market access trends and challenges for generic drugs, including intellectual property barriers, pricing pressures, and emerging markets.

ใ‚ญใƒฃใƒชใ‚ขใƒ‘ใ‚น

ๅ…ฅๅญฆ่ฆไปถ

  • ไธป้กŒใฎๅŸบๆœฌ็š„ใช็†่งฃ
  • ่‹ฑ่ชžใฎ็ฟ’็†Ÿๅบฆ
  • ใ‚ณใƒณใƒ”ใƒฅใƒผใ‚ฟใƒผใจใ‚คใƒณใ‚ฟใƒผใƒใƒƒใƒˆใ‚ขใ‚ฏใ‚ปใ‚น
  • ๅŸบๆœฌ็š„ใชใ‚ณใƒณใƒ”ใƒฅใƒผใ‚ฟใƒผใ‚นใ‚ญใƒซ
  • ใ‚ณใƒผใ‚นๅฎŒไบ†ใธใฎ็Œฎ่บซ

ไบ‹ๅ‰ใฎๆญฃๅผใช่ณ‡ๆ ผใฏไธ่ฆใ€‚ใ‚ขใ‚ฏใ‚ปใ‚ทใƒ“ใƒชใƒ†ใ‚ฃใฎใŸใ‚ใซ่จญ่จˆใ•ใ‚ŒใŸใ‚ณใƒผใ‚นใ€‚

ใ‚ณใƒผใ‚น็Šถๆณ

ใ“ใฎใ‚ณใƒผใ‚นใฏใ€ใ‚ญใƒฃใƒชใ‚ข้–‹็™บใฎใŸใ‚ใฎๅฎŸ็”จ็š„ใช็Ÿฅ่ญ˜ใจใ‚นใ‚ญใƒซใ‚’ๆไพ›ใ—ใพใ™ใ€‚ใใ‚Œใฏ๏ผš

  • ่ชๅฏใ•ใ‚ŒใŸๆฉŸ้–ขใซใ‚ˆใฃใฆ่ชๅฎšใ•ใ‚Œใฆใ„ใชใ„
  • ่ชๅฏใ•ใ‚ŒใŸๆฉŸ้–ขใซใ‚ˆใฃใฆ่ฆๅˆถใ•ใ‚Œใฆใ„ใชใ„
  • ๆญฃๅผใช่ณ‡ๆ ผใฎ่ฃœๅฎŒ

ใ‚ณใƒผใ‚นใ‚’ๆญฃๅธธใซๅฎŒไบ†ใ™ใ‚‹ใจใ€ไฟฎไบ†่จผๆ˜Žๆ›ธใ‚’ๅ—ใ‘ๅ–ใ‚Šใพใ™ใ€‚

ใชใœไบบใ€…ใŒใ‚ญใƒฃใƒชใ‚ขใฎใŸใ‚ใซ็งใŸใกใ‚’้ธใถใฎใ‹

ใƒฌใƒ“ใƒฅใƒผใ‚’่ชญใฟ่พผใฟไธญ...

ใ‚ˆใใ‚ใ‚‹่ณชๅ•

ใ“ใฎใ‚ณใƒผใ‚นใ‚’ไป–ใฎใ‚ณใƒผใ‚นใจๅŒบๅˆฅใ™ใ‚‹ใ‚‚ใฎใฏไฝ•ใงใ™ใ‹๏ผŸ

ใ‚ณใƒผใ‚นใ‚’ๅฎŒไบ†ใ™ใ‚‹ใฎใซใฉใ‚Œใใ‚‰ใ„ๆ™‚้–“ใŒใ‹ใ‹ใ‚Šใพใ™ใ‹๏ผŸ

WhatSupportWillIReceive

IsCertificateRecognized

WhatCareerOpportunities

ใ„ใคใ‚ณใƒผใ‚นใ‚’้–‹ๅง‹ใงใใพใ™ใ‹๏ผŸ

ใ‚ณใƒผใ‚นใฎๅฝขๅผใจๅญฆ็ฟ’ใ‚ขใƒ—ใƒญใƒผใƒใฏไฝ•ใงใ™ใ‹๏ผŸ

ใ‚ณใƒผใ‚นๆ–™้‡‘

ๆœ€ใ‚‚ไบบๆฐ—
ใƒ•ใ‚กใ‚นใƒˆใƒˆใƒฉใƒƒใ‚ฏ๏ผš GBP £140
1ใƒถๆœˆใงๅฎŒไบ†
ๅŠ ้€Ÿๅญฆ็ฟ’ใƒ‘ใ‚น
  • ้€ฑ3-4ๆ™‚้–“
  • ๆ—ฉๆœŸ่จผๆ˜Žๆ›ธ้…้”
  • ใ‚ชใƒผใƒ—ใƒณ็™ป้Œฒ - ใ„ใคใงใ‚‚้–‹ๅง‹
Start Now
ใ‚นใ‚ฟใƒณใƒ€ใƒผใƒ‰ใƒขใƒผใƒ‰๏ผš GBP £90
2ใƒถๆœˆใงๅฎŒไบ†
ๆŸ”่ปŸใชๅญฆ็ฟ’ใƒšใƒผใ‚น
  • ้€ฑ2-3ๆ™‚้–“
  • ้€šๅธธใฎ่จผๆ˜Žๆ›ธ้…้”
  • ใ‚ชใƒผใƒ—ใƒณ็™ป้Œฒ - ใ„ใคใงใ‚‚้–‹ๅง‹
Start Now
ไธกๆ–นใฎใƒ—ใƒฉใƒณใซๅซใพใ‚Œใ‚‹ใ‚‚ใฎ๏ผš
  • ใƒ•ใƒซใ‚ณใƒผใ‚นใ‚ขใ‚ฏใ‚ปใ‚น
  • ใƒ‡ใ‚ธใ‚ฟใƒซ่จผๆ˜Žๆ›ธ
  • ใ‚ณใƒผใ‚นๆ•™ๆ
ใ‚ชใƒผใƒซใ‚คใƒณใ‚ฏใƒซใƒผใ‚ทใƒ–ไพกๆ ผ โ€ข ้š ใ‚ŒใŸๆ–™้‡‘ใ‚„่ฟฝๅŠ ่ฒป็”จใชใ—

ใ‚ณใƒผใ‚นๆƒ…ๅ ฑใ‚’ๅ–ๅพ—

่ฉณ็ดฐใชใ‚ณใƒผใ‚นๆƒ…ๅ ฑใ‚’ใŠ้€ใ‚Šใ—ใพใ™

ไผš็คพใจใ—ใฆๆ”ฏๆ‰•ใ†

ใ“ใฎใ‚ณใƒผใ‚นใฎๆ”ฏๆ‰•ใ„ใฎใŸใ‚ใซไผš็คพ็”จใฎ่ซ‹ๆฑ‚ๆ›ธใ‚’ใƒชใ‚ฏใ‚จใ‚นใƒˆใ—ใฆใใ ใ•ใ„ใ€‚

่ซ‹ๆฑ‚ๆ›ธใงๆ”ฏๆ‰•ใ†

ใ‚ญใƒฃใƒชใ‚ข่จผๆ˜Žๆ›ธใ‚’ๅ–ๅพ—

ใ‚ตใƒณใƒ—ใƒซ่จผๆ˜Žๆ›ธใฎ่ƒŒๆ™ฏ
ADVANCED CERTIFICATE IN BIOPHARMA MARKET ACCESS FOR GENERICS
ใซๆŽˆไธŽใ•ใ‚Œใพใ™
ๅญฆ็ฟ’่€…ๅ
ใงใƒ—ใƒญใ‚ฐใƒฉใƒ ใ‚’ๅฎŒไบ†ใ—ใŸไบบ
London School of International Business (LSIB)
ๆŽˆไธŽๆ—ฅ
05 May 2025
ใƒ–ใƒญใƒƒใ‚ฏใƒใ‚งใƒผใƒณID๏ผš s-1-a-2-m-3-p-4-l-5-e
ใ“ใฎ่ณ‡ๆ ผใ‚’LinkedInใƒ—ใƒญใƒ•ใ‚ฃใƒผใƒซใ€ๅฑฅๆญดๆ›ธใ€ใพใŸใฏCVใซ่ฟฝๅŠ ใ—ใฆใใ ใ•ใ„ใ€‚ใ‚ฝใƒผใ‚ทใƒฃใƒซใƒกใƒ‡ใ‚ฃใ‚ขใ‚„ใƒ‘ใƒ•ใ‚ฉใƒผใƒžใƒณใ‚นใƒฌใƒ“ใƒฅใƒผใงๅ…ฑๆœ‰ใ—ใฆใใ ใ•ใ„ใ€‚
SSB Logo

4.8
ๆ–ฐ่ฆ็™ป้Œฒ